Science & Health · Health · 6 outlets (L 2 · C 2 · R 1 · 1 not rated)
FDA orders new vision-loss warning on GLP-1 drugs
The FDA is requiring all GLP-1 medications, including Ozempic and Wegovy, to add label warnings about a rare eye condition that can cause sudden vision loss. Users are urged to talk to their providers about eyesight changes.[2, 5, 6] The condition is known as nonarteritic anterior ischemic optic neuropathy, or NAION, according to Fast Company.[6] The Conversation reported that doctors often call the condition a stroke of the eye, and that patients should know the symptoms and seek immediate treatment if they occur.[1]
The label change puts a spotlight on a risk patients and doctors need to weigh alongside the drugs' weight-loss and diabetes benefits, The Political Insider reported.[5] Users are being urged to talk with their healthcare providers about any changes in their eyesight.[5]
Why it matters All GLP-1 drug makers must now include the new safety warning on their labels.[6]
Covered by The Guardian, CBS News, The Political Insider and 3 more
Background FDA Issues New Warning For GLP-1 Drugs Over Rare Eye Condition—Here’s What To Know
How balanced is this coverage?
Of the 5 rated outlets that covered it, 2 are left of center, 2 are center and 1 is right of center (1 of them in the Right group). 1 more is not rated.
Too few left- or right-leaning outlets to compare: 2 of 42 left-leaning, 2 of 33 center and 1 of 38 right-leaning outlets covered it.
- Left: none.
- Leans left: The Conversation (−0.73), The Guardian (−0.70).
- Center: CBS News (−0.14), Forbes (+0.19).
- Leans right: none.
- Right: The Political Insider (+2.65).
Not rated Fast Company. Not placed: they have no lean score.
Each dot is an outlet that covered it, placed by its audience-lean score (Eady et al. 2025), which measures who shares its links, not how accurate it is. The ticks under the line are all 113 rated outlets Tare reads.